EPOCH Trial
EPOCH is a level 1, phase III randomised controlled trial using transarterial radiation therapy for mCRC liver metastases that demonstrated statistically significant improvements in both Progression-Free Survival (PFS) and Hepatic Progression-Free Survival (hPFS) in patients who progressed on first-line chemotherapy.
Trial Objective & Design
Trial Objective
To evaluate the safety and efficacy of TheraSphere Y-90 Glass Microspheres combined with second-line therapy (oxaliplatin- or irinotecan-based chemotherapy) in patients with mCRC of the liver.
Trial Design
An open-label, prospective, multicenter, phase III trial of 428 patients randomised 1:1 to treatment arm (TheraSphere + second-line chemotherapy) vs. control arm (second-line chemotherapy alone) across 95 centers in 12 countries, including North America, Europe and Asia.
![EPOCH Trial design graphic](https://www.bostonscientific.com/en-EU/medical-specialties/interventional-radiology/interventional-oncology/latest-evidence/epoch-trial-design/_jcr_content/fullBleedTileContent-par/fullbleedtile_copy_c_565485037/maincontentFullBleed-par/image.img.EPOCH%20Data%20Sheet%20vF.jpg)
Unilobar or Bilobar Disease, KRAS Status (Mutant or Wild type, 1st Line Chemo (Irinotecan or oxaliplatin based)
Primary Endpoints
Progression-free survival (PFS) and hepatic PFS (hPFS)
- Time from randomisation to progression or death by RECIST 1.1 or death
- Blinded independent central review (BICR)
Both primary endpoints successfully met
TheraSphere Y-90 Glass Microspheres used in combination with chemotherapy as a second-line treatment demonstrated statistically significant improvements in both PFS and hPFS in patients who progressed on first-line chemotherapy.
Progression Free Survival2
![]() |
Patients receiving TheraSphere with second-line chemo were 31% less likely to experience disease progression or death (due to any cause) vs. chemo alone. |
![Progression free survival chart](https://www.bostonscientific.com/en-EU/medical-specialties/interventional-radiology/interventional-oncology/latest-evidence/epoch-trial-design/_jcr_content/fullBleedTileContent-par/fullbleedtile_copy_c_565485037/maincontentFullBleed-par/fullbleedtile_112023/maincontentFullBleed-par/image.img.pfs-chart.png)
Hepatic Progression Free Survival3
![]() |
Patients receiving TheraSphere with second-line chemo were 41% less likely to experience hepatic disease progression or death (due to any cause) vs. chemo alone. |
![Hepatic Progression Free Survival chart](https://www.bostonscientific.com/en-EU/medical-specialties/interventional-radiology/interventional-oncology/latest-evidence/epoch-trial-design/_jcr_content/fullBleedTileContent-par/fullbleedtile_copy_c_565485037/maincontentFullBleed-par/fullbleedtile_112023/maincontentFullBleed-par/image_1613575266.img.hPFS-chart.png)
Secondary Endpoints
Median Overall Survival (in months):
- Intent-to-Treat (ITT): 14.0 vs. 14.4 for TS+Chemo (N=215) vs. Chemo alone (N=213) (1-sided p-value: 0.7229)
- Per-Protocol (PP): 15.2 vs. 14.3 for TS+Chemo (N=115) vs. Chemo alone (N=173) (1-sided p-value: 0.3841)*
* TS+Chemo (N=100) and Chemo alone (N=40) patients excluded from Per Protocol analysis due to major deviations
Tumour Response4
Patients receiving TheraSphere Y-90 with second-line chemotherapy showed an Objective Response Rate (ORR) of 34.0% vs. 21.1% for the control arm; a difference of 12.8%.
Additional Analyses
Time to Start of Subsequent Therapy & Quality of Life
The addition of TheraSphere Y-90 to second-line chemotherapy extended the time to start of subsequent therapy without compromising quality of life.
Time to Start of Subsequent Therapy5
![time to start of subsequent therapy](https://www.bostonscientific.com/en-EU/medical-specialties/interventional-radiology/interventional-oncology/latest-evidence/epoch-trial-design/_jcr_content/fullBleedTileContent-par/fullbleedtile_copy_c_565485037/maincontentFullBleed-par/image_902609853_copy.img.time-to-subsequent-therapy-km-ts-2.png)
Time to Deterioration of Quality of Life6
![time to deterioration of quality of life](https://www.bostonscientific.com/en-EU/medical-specialties/interventional-radiology/interventional-oncology/latest-evidence/epoch-trial-design/_jcr_content/fullBleedTileContent-par/fullbleedtile_copy_c_565485037/maincontentFullBleed-par/image_1108096140_cop.img.ttdqol-km-ts-2.png)
Key Patient & Disease Characteristics
TheraSphere + Chemo (N = 215) | Chemo (N = 213) | |
Median Age (y) | 63.0 | 60.0 |
Male | 135 (62.8%) | 138 (64.8%) |
Region North America Europe Asia | 63 (29.3%) 131 (60.9%) 21 (9.8%) | 56 (26.3%) 145 (68.1%) 12 (5.6%) |
ECOG 0 | 119 (55.3%) | 133 (62.4%) |
Albumin ≥ Site LLN | 182 (84.7%) | 177 (83.1%) |
CEA ≥ 35ng/mL | 116 (54.0%) | 105 (49.3%) |
KRAS Status Mutant Wild Type | 100 (46.5%) 115 (53.5%) | 101 (47.4%) 112 (52.6%) |
Bilobar disease | 176 (81.9%) | 173 (81.2%) |
Liver tumor burden at baseline by BICR < 10% ≥ 10% to < 25% ≥ 25% Missing | 124 (57.7%) 54 (25.1%) 29 (13.5%) 8 (3.7%) | 121 (56.8%) 47 (22.1%) 28 (13.1%) 17 (8.0%) |
Maximum liver lesion size ≥ 4cm | 162 (75.3%) | 142 (66.7%) |
Primary tumor in situ | 83 (38.6%) | 69 (32.4%) |
Left side primary tumor location | 150 (69.8%) | 136 (63.8%) |
Extrahepatic metastases at baseline | 113 (52.6%) | 95 (44.6%) |
Treatment Characteristics
TheraSphere + Chemo (N = 215) | Chemo (N = 213) | |
Received Assigned Therapy | 187 (87.0%) | 191 (89.7%) |
2nd Line Chemo Administered | 203 (94.4%) | 191 (89.7%) |
Irinotecan-based / Mean Number of Cycles | 130 (60.5%) / 9.0 | 123 (57.7%) / 9.5 |
Oxaliplatin-based / Mean Number of Cycles | 73 (34.0%) / 8.5 | 68 (31.9%) / 8.8 |
Biological Agent | 88 (40.9%) | 93 (43.7%) |
TheraSphere Y-90 Glass Microspheres Treatment | ||
---|---|---|
Median time to Y-90, days (range) | 25 (12, 90) | NA |
The addition of TheraSphere Y-90 to second-line chemotherapy did not increase chemo-related adverse events and no new safety signals were identified.1